Trial
NCT01728259
First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Barbara Ann Karmanos Cancer Institute
Collaborators
—
Condition
Light Chain Deposition Disease
Intervention
pomalidomide
Why stopped
FDA placed the study on a clinical hold, due to the concerns by the FDA and Health Canada, Celgene decided to permanently close the study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-05-09